FEQ1 Stock Overview
A pharmaceutical company, engages in the research, development, manufacture, and marketing of pharmaceutical products and specialties, as well as accessories authorized foodstuffs, dietary and personal care products, and cosmetics. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
Rewards
Risk Analysis
No risks detected for FEQ1 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Laboratorio Reig Jofre, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.52 |
| 52 Week High | €3.28 |
| 52 Week Low | €2.26 |
| Beta | 0.91 |
| 1 Month Change | -5.97% |
| 3 Month Change | -8.70% |
| 1 Year Change | 7.69% |
| 3 Year Change | -24.21% |
| 5 Year Change | -1.56% |
| Change since IPO | 12.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| FEQ1 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -4.5% | -0.2% | -0.1% |
| 1Y | 7.7% | -16.7% | 7.4% |
Return vs Industry: FEQ1 exceeded the German Pharmaceuticals industry which returned -16.7% over the past year.
Return vs Market: FEQ1 matched the German Market which returned 7.4% over the past year.
Price Volatility
| FEQ1 volatility | |
|---|---|
| FEQ1 Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: FEQ1 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: FEQ1's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1929 | 1,323 | Ignasi Reig | www.reigjofre.com |
Laboratorio Reig Jofre, S.A., a pharmaceutical company, engages in the research, development, manufacture, and marketing of pharmaceutical products and specialties, as well as accessories authorized foodstuffs, dietary and personal care products, and cosmetics. The company offers nutritional and parapharmacy products. Its products also include pharmaceutical technologies products, such as antibiotics, and injectables and other products; specialty pharmacare products, which include skin, hair, nails, joint health and pain, and women’s health; and food supplements under the Forté Pharma brand.
Laboratorio Reig Jofre, S.A. Fundamentals Summary
| FEQ1 fundamental statistics | |
|---|---|
| Market cap | €205.75m |
| Earnings (TTM) | €9.55m |
| Revenue (TTM) | €333.69m |
21.5x
P/E Ratio0.6x
P/S RatioIs FEQ1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FEQ1 income statement (TTM) | |
|---|---|
| Revenue | €333.69m |
| Cost of Revenue | €144.54m |
| Gross Profit | €189.15m |
| Other Expenses | €179.60m |
| Earnings | €9.55m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.12 |
| Gross Margin | 56.68% |
| Net Profit Margin | 2.86% |
| Debt/Equity Ratio | 24.7% |
How did FEQ1 perform over the long term?
See historical performance and comparisonDividends
1.6%
Current Dividend Yield34%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/06 05:52 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Laboratorio Reig Jofre, S.A. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Francisco Ruiz | BNP Paribas Exane |
| Luis Esteban Arribas | Lighthouse-IEAF Servicios de Analisis |